- Nachrichtendetail
-
06.06.2024 14:47:50 - dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
ABBVIE | A1J84E | NYSE | 167,250 | 05.07.24 03:00:54 | +3,410 | +2,08% | 167,000 | 167,280 | 164,720 | 167,250 |
